Dr. Monjazeb is a clinician scientist in oncology leading the clinical care of patients, a high-powered basic science research enterprise, and cutting-edge human clinical trials. His research has two major themes. The first focuses on understanding mechanisms of resistance to cancer immunotherapy and exploring combinatorial strategies, including combined radiotherapy and immunotherapy, to overcome resistance. The second is understanding how aging and obesity affect inflammation and immunity in the context of cancer development, progression, and therapy. His research is translational in nature spanning from basic mechanistic studies to murine models to large animal companion canine clinical trials and human clinical trials.  His accomplishments in this field have been recognized by institutional and national leadership positions in translational and clinical research. He has designed, initiated, and served as principal investigator for a number of novel institutional clinical trials testing combinatorial immunotherapy strategies as well as national multi-institutional clinical trials through the ETCTN and SWOG/NRG.